These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 25627111)

  • 1. Effects of human arylamine N-acetyltransferase I knockdown in triple-negative breast cancer cell lines.
    Tiang JM; Butcher NJ; Minchin RF
    Cancer Med; 2015 Apr; 4(4):565-74. PubMed ID: 25627111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule inhibition of arylamine N-acetyltransferase Type I inhibits proliferation and invasiveness of MDA-MB-231 breast cancer cells.
    Tiang JM; Butcher NJ; Minchin RF
    Biochem Biophys Res Commun; 2010 Feb; 393(1):95-100. PubMed ID: 20100460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic and small molecule inhibition of arylamine N-acetyltransferase 1 reduces anchorage-independent growth in human breast cancer cell line MDA-MB-231.
    Stepp MW; Doll MA; Carlisle SM; States JC; Hein DW
    Mol Carcinog; 2018 Apr; 57(4):549-558. PubMed ID: 29315819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of β-catenin decreases the tumorigenicity, but promotes epithelial-mesenchymal transition in breast cancer cells.
    Cai K; Jiang L; Wang J; Zhang H; Wang X; Cheng D; Dou J
    J Cancer Res Ther; 2014; 10(4):1063-70. PubMed ID: 25579555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNAi-mediated knock-down of arylamine N-acetyltransferase-1 expression induces E-cadherin up-regulation and cell-cell contact growth inhibition.
    Tiang JM; Butcher NJ; Cullinane C; Humbert PO; Minchin RF
    PLoS One; 2011 Feb; 6(2):e17031. PubMed ID: 21347396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of invasion and metastasis of triple-negative breast cancer lines by pharmacological or genetic inhibition of slug activity.
    Ferrari-Amorotti G; Chiodoni C; Shen F; Cattelani S; Soliera AR; Manzotti G; Grisendi G; Dominici M; Rivasi F; Colombo MP; Fatatis A; Calabretta B
    Neoplasia; 2014 Dec; 16(12):1047-58. PubMed ID: 25499218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deletion of arylamine N-acetyltransferase 1 in MDA-MB-231 human breast cancer cells reduces primary and secondary tumor growth in vivo with no significant effects on metastasis.
    Doll MA; Ray AR; Salazar-González RA; Shah PP; Vega AA; Sears SM; Krueger AM; Hong KU; Beverly LJ; Hein DW
    Mol Carcinog; 2022 May; 61(5):481-493. PubMed ID: 35133049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockout of human arylamine N-acetyltransferase 1 (NAT1) in MDA-MB-231 breast cancer cells leads to increased reserve capacity, maximum mitochondrial capacity, and glycolytic reserve capacity.
    Carlisle SM; Trainor PJ; Doll MA; Stepp MW; Klinge CM; Hein DW
    Mol Carcinog; 2018 Nov; 57(11):1458-1466. PubMed ID: 29964355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect arylamine N-acetyltransferase 1 on morphology, adhesion, migration, and invasion of MDA-MB-231 cells: role of matrix metalloproteinases and integrin αV.
    Li P; Butcher NJ; Minchin RF
    Cell Adh Migr; 2020 Dec; 14(1):1-11. PubMed ID: 31910058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role for human arylamine N-acetyltransferase 1 in the methionine salvage pathway.
    Witham KL; Minchin RF; Butcher NJ
    Biochem Pharmacol; 2017 Feb; 125():93-100. PubMed ID: 27865712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Establishment of a bioluminescent MDA-MB-231 cell line for in vivo imaging of human triple-negative breast cancer xenograft].
    Wang K; Xie SM; He JJ; Ren Y; Xia HB; Zhang XW
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Nov; 31(11):1812-8. PubMed ID: 22126756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arylamine
    Li P; Butcher NJ; Minchin RF
    Mol Pharmacol; 2019 Nov; 96(5):573-579. PubMed ID: 31444237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9 knockout of human arylamine N-acetyltransferase 1 in MDA-MB-231 breast cancer cells suggests a role in cellular metabolism.
    Carlisle SM; Trainor PJ; Hong KU; Doll MA; Hein DW
    Sci Rep; 2020 Jun; 10(1):9804. PubMed ID: 32555504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The monoamine oxidase-A inhibitor clorgyline promotes a mesenchymal-to-epithelial transition in the MDA-MB-231 breast cancer cell line.
    Satram-Maharaj T; Nyarko JN; Kuski K; Fehr K; Pennington PR; Truitt L; Freywald A; Lukong KE; Anderson DH; Mousseau DD
    Cell Signal; 2014 Dec; 26(12):2621-32. PubMed ID: 25152370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of a bioluminescent MDA-MB-231 cell line for human triple-negative breast cancer research.
    Wang K; Xie S; Ren Y; Xia H; Zhang X; He J
    Oncol Rep; 2012 Jun; 27(6):1981-9. PubMed ID: 22446691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
    Liu J; Chen X; Ward T; Pegram M; Shen K
    Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fucoidan induces changes in the epithelial to mesenchymal transition and decreases metastasis by enhancing ubiquitin-dependent TGFβ receptor degradation in breast cancer.
    Hsu HY; Lin TY; Hwang PA; Tseng LM; Chen RH; Tsao SM; Hsu J
    Carcinogenesis; 2013 Apr; 34(4):874-84. PubMed ID: 23275155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin.
    Shah P; Gau Y; Sabnis G
    Breast Cancer Res Treat; 2014 Jan; 143(1):99-111. PubMed ID: 24305977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma.
    Yang MH; Chen CL; Chau GY; Chiou SH; Su CW; Chou TY; Peng WL; Wu JC
    Hepatology; 2009 Nov; 50(5):1464-74. PubMed ID: 19821482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Arylamine
    Carlisle SM; Trainor PJ; Doll MA; Hein DW
    Front Pharmacol; 2021; 12():803254. PubMed ID: 35046826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.